Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10082167 | 0.90 | AADAT (0.44) | AADATTMEM97SIGMAR1PDE5APREP | |
| SCHEMBL10082168 | 0.90 | AADAT (0.44) | AADATTMEM97SIGMAR1PDE5APREP | |
| SCHEMBL10082942 | 0.90 | AADAT (0.42) | AADATTMEM97SIGMAR1PDE5APREP | |
| SCHEMBL10082157 | 0.84 | AADAT (0.44) | AADATTMEM97SIGMAR1PREPNPSR1 | |
| SCHEMBL16276293 | 0.81 | HCRTR1 (0.48) | AADATTMEM97SIGMAR1PREPNPSR1 | |
| SCHEMBL10081950 | 0.78 | AADAT (0.44) | AADATTMEM97SIGMAR1PREPNPSR1 | |
| SCHEMBL2379314 | 0.77 | TMEM97 (0.60) | AADATTMEM97SIGMAR1PREPACE2 | |
| SCHEMBL10082933 | 0.77 | PRCP (0.45) | — | |
| SCHEMBL12075233 | 0.76 | HCRTR1 (0.59) | AADAT | |
| SCHEMBL3209134 | 0.76 | HCRTR1 (0.59) | AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815849-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN R&D IRELAND (IE) | 2014-08-26 | — | — | US | disclosed |
| US-8815849-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN R&D IRELAND (IE) | 2014-08-26 | — | — | US | disclosed |
| EP-2598498-B1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | JANSSEN R & D IRELAND (IE) | 2014-07-09 | — | — | EP | disclosed |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | JANSSEN R&D IRELAND (IL) | 2013-05-16 | — | — | US | disclosed |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | JANSSEN R&D IRELAND (IL) | 2013-05-16 | — | — | US | disclosed |
| WO-2012013643-A1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | AADAT 2837/4885TMEM97 2931/4885SIGMAR1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.